Online CME/Enduring Materials

Emerging Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: Highlights from ASH 2018
This enduring panel discussion will review the efficacy and safety of emerging treatment options for patients with RRMM and discuss the clinical practice implications of these therapies in the context of currently approved therapies and treatment algorithms. This activity will also address practical strategies to individualize RRMM treatment paradigms, while considering both approved and investigational strategies, and accounting for patient-specific factors.

Optimizing the Use of Targeted Therapies into CLL Treatment Paradigms: Applying the Latest Evidence into Practice
This interactive activity features 2 leading experts in CLL who discuss and debate the latest advances regarding novel and emerging targeted therapies for patients with CLL, as well as discuss the evolving role of prognostic molecular biomarkers in targeted therapy initiation and treatment selection, highlighting key data presented at the 2018 Annual Meeting and Exposition of the American Society of Hematology (ASH).

Evolving Considerations in Immuno-Oncology: Bridging the Gaps Between Research and Clinical Care Program E117651
The goal of this international, on-demand web portal is to inform oncology HCPs on the clinical rationale of checkpoint inhibitor (CPI) use across various cancers; the latest efficacy and safety data that may inform patient selection; practical strategies for effective CPI use and the management of treatment-related adverse events; and potential region-specific variations in CPI clinical utility.

Practicing in an Era of Chemotherapy-Free Regimens for Relapsed/Refractory Chronic Lymphocytic Leukemia

1.00 AMA PRA Category 1 Credits ^TM from June 28, 2019 thru June 28, 2020.

This educational curriculum will improve the ability of learners to: assess key prognostic, predictive, and clinical factors that drive the factors for considering 2^nd line therapy for patients with CLL;  utilize the most recent evidence-based guidelines for the care of individuals with  R/R CLL; describe key clinical trial results and subset analyses demonstrating the efficacy and safety of targeted regimens in the R/R CLL and understand the implications of these data for practice; understand the clinical trial endpoints of overall survival, response rate, and clearance of minimal residual disease of venetoclax-rituxumab combination  therapy compared with bendamustine-rituxumab; and employ effective communication strategies using core SDM principles with patients with CLL and their caregivers. It is anticipated that these practice improvements will lead, by extension, to improved patient outcomes.

Preview Mode: Emergence of Chemotherapy-Free Regimens for Previously Untreated and Relapsed/Refractory CLL: Highlights from ASCO 2019 E11717-1

This educational curriculum will improve the ability of learners to: assess key prognostic, predictive, and clinical factors that drive the factors for considering 2^nd line therapy for patients with CLL;  utilize the most recent evidence-based guidelines for the care of individuals with  R/R CLL; describe key clinical trial results and subset analyses demonstrating the efficacy and safety of targeted regimens in the R/R CLL and understand the implications of these data for practice; understand the clinical trial endpoints of overall survival, response rate, and clearance of minimal residual disease of venetoclax-rituxumab combination  therapy compared with bendamustine-rituxumab; and employ effective communication strategies using core SDM principles with patients with CLL and their caregivers. It is anticipated that these practice improvements will lead, by extension, to improved patient outcomes.

Clinical Updates in Chronic Myeloid Leukemia

MPT is the fastest online destination for clinicians seeking breaking medical news and education. News-Driven engagement means access to over 1.1 million readers on the site each month and over 730,000 validated physician members.
 

Provider Tobacco and Nicotine Counseling for Adults and Adolescents
2.25 AMA PRA Category 1 CreditsTM